Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9P0K1
UPID:
ADA22_HUMAN
Alternative names:
Metalloproteinase-disintegrin ADAM22-3; Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 2
Alternative UPACC:
Q9P0K1; O75075; O75076; Q9P0K2; Q9UIA1; Q9UKK2
Background:
Disintegrin and metalloproteinase domain-containing protein 22 (ADAM22) serves as a probable ligand for integrin in the brain, playing a pivotal role in regulating cell adhesion, spreading, and proliferation inhibition. It acts as a neuronal receptor for LGI1, showcasing its importance in neural communication and synaptic organization.
Therapeutic significance:
ADAM22's involvement in Developmental and Epileptic Encephalopathy 61 (DEE61), a severe early-onset epilepsy, underscores its therapeutic potential. Understanding ADAM22's function could lead to novel interventions for DEE61, offering hope for improved treatments and outcomes.